Faeth Therapeutics, Inc. (FTH) shareholders
FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.65−2.70 (-20.22%)
Close on Nov 12, 2026Market cap $275.20MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
54.5%
14M of 26M shares
Institutional holders
45
22 new, 7 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
49 buys · 45 sales
Net bought $250.44K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| VK Services, LLC Joint filing with Vinod Khosla (10.20%), Khosla Ventures VI, LP (6.40%) and 1 more | 2,632,232 | 10.20% | 13G (passive) | Jun 15, 2026 |
| S2G Investments, LLC | 2,575,401 | 9.99% | 13G (passive) | Jun 15, 2026 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (7.80%), Averill Master Fund, Ltd. (6.70%) | 2,020,103 | 7.80% | 13G (passive) | Jun 15, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (9.60%), Israel A. Englander (9.60%) and 1 more | 128,761 | 9.60% | 13G (passive) | Feb 24, 2026 |
| Ortav Yehudai Joint filing with Trails Edge Capital Partners, LP (9.90%), Trails Edge Biotechnology Master Fund, LP (9.90%) | 126,010 | 9.90% | 13G (passive) | Feb 18, 2026 |
| David Johnson Joint filing with Caligan Partners LP (9.40%) | 126,002 | 9.40% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,020,103 | 7.82% | $50.50M | +1,985,554 | 0.92% |
| Avoro Capital Advisors LLC | 1,444,039 | 5.59% | $36.10M | New | 0.32% |
| Baker Bros. Advisors LP | 1,286,411 | 4.98% | $32.16M | New | 0.16% |
| Balyasny Asset Management L.P. | 1,042,198 | 4.03% | $26.05M | +1,025,993 | 0.03% |
| Cormorant Asset Management, LP | 1,028,242 | 3.98% | $7.66M | +722,020 | 0.39% |
| Vivo Capital, LLC | 722,020 | 2.79% | $18.05M | – | 1.65% |
| Ra Capital Management, L.P. | 722,020 | 2.79% | $18.05M | New | 0.16% |
| Logos Global Management LP | 722,020 | 2.79% | $18.05M | +692,020 | 0.78% |
| Fairmount Funds Management LLC | 722,020 | 2.79% | $18.05M | New | 1.19% |
| Caligan Partners LP | 629,467 | 2.44% | $15.74M | +503,465 | 0.74% |
| B Group, Inc. | 610,169 | 2.36% | $15.25M | New | 7.16% |
| Trails Edge Capital Partners, LP | 515,335 | 1.99% | $12.88M | +390,335 | 2.05% |
| Franklin Resources Inc | 494,516 | 1.91% | $12.36M | +361,010 | 0.00% |
| ADAR1 Capital Management, LLC | 361,010 | 1.40% | $9.03M | New | 0.41% |
| Octagon Capital Advisors LP | 361,010 | 1.40% | $9.03M | New | 0.81% |
| Marshall Wace, Llp | 206,508 | 0.80% | $5.16M | +140,778 | 0.00% |
| Boxer Capital Management, LLC | 180,505 | 0.70% | $4.51M | New | 0.34% |
| Patient Square Capital LP | 175,050 | 0.68% | $4.38M | New | 0.68% |
| Alyeska Investment Group, L.P. | 144,404 | 0.56% | $3.61M | New | 0.01% |
| Affinity Asset Advisors, LLC | 144,404 | 0.56% | $3.61M | New | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 14M | 54.5% | 22 / 17 | 2 / 7 | 12M | 1M |
| Q1 2026 | 30 | 2M | 8.9% | 22 / 3 | 1 / 2 | 2M | 0M |
| Q4 2025 | 10 | 0M | 0.2% | 2 / 1 | 4 / 1 | 0M | 0M |
| Q3 2025 | 9 | 0M | 0.2% | 1 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 10 | 0M | 0.3% | 10 / 0 | 0 / 1 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
11 funds held FTH in Q2 2026, 20% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | 180,711 | 0.70% | $4.92M | 0.43% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 10,115 | 0.04% | $252.88K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 4,576 | 0.02% | $96.74K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 3,192 | 0.01% | $79.80K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 1,416 | 0.01% | $29.93K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,253 | 0.00% | $26.49K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 578 | 0.00% | $12.22K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 210 | 0.00% | $5.25K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 41 | 0.00% | $1.03K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anand Kiran Parikh | President and CEO, Director | 817,699 | 3.16% | Nov 3, 2026 |
| John Celebi | PRESIDENT AND CEO, Director | 105,862 | 0.41% | Feb 26, 2025 |
| Josiah Craver | PAO | – | – | Jul 23, 2026 |
| Brian C. Stephenson | Chief Financial Officer | 46,088 | 0.18% | Jul 1, 2026 |
| Christopher Gerry | President & PEO | 1,574 | 0.01% | Jun 12, 2026 |
| der Horst Edward van | CHIEF SCIENTIFIC OFFICER | 59,794 | 0.23% | Feb 26, 2025 |
| Stephanie Krebs | Chief Business Officer | – | – | Feb 14, 2025 |
| Adam Schayowitz | Director | – | – | Oct 27, 2026 |
| Karen H. Vousden | Director | 42,631 | 0.16% | Sep 15, 2026 |
| Saira Ramasastry | Director | – | – | Jun 16, 2026 |
| Stephen M. Hahn | Director | 44,763 | 0.17% | Jun 16, 2026 |
| Bob Holmen | Director | 25,598 | 0.10% | Jun 12, 2026 |
| Phillip B. Donenberg | Director | – | – | Jun 12, 2026 |
| Kristian Humer | Director | 8,932 | 0.03% | May 23, 2025 |
| Thomas G. Ricks | Director | 343,863 | 1.33% | May 23, 2025 |
| William R. Ringo | Director | 23,399 | 0.09% | May 23, 2025 |
| Vinod Khosla | 10% owner | 1,643,349 | 6.36% | Jul 28, 2026 |
| VK Services, LLC | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures VI, L.P. | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Associates VI, LLC | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Seed D, L.P. | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Seed Associates D, LLC | 10% owner | – | – | Jul 28, 2026 |
| BioPharma Inc Cambrian | 10% owner | 130,142 | 0.50% | Jun 1, 2026 |
| James Peyer | 10% owner | 286,125 | 1.11% | Jun 1, 2026 |
| Group Management Llc Millennium | 10% owner | – | – | May 15, 2026 |
| Israel A. Englander | 10% owner | – | – | May 15, 2026 |
| Opportunities Ii Llc Ics | 10% owner | 127,095 | 0.49% | May 15, 2026 |
| Management Llc Millennium | 10% owner | 147,731 | 0.57% | May 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Anand Kiran Parikh President and CEO, Director | Oct 30, 2026 | Gift | +100,000 | – | – | 100,000 |
| Anand Kiran Parikh President and CEO, Director | Oct 30, 2026 | Gift | −100,000 | – | – | 717,699 |
| Brian C. Stephenson Chief Financial Officer | Jul 1, 2026 | Buy | +4,400 | $23.40 | $102.96K | 46,088 |
| Brian C. Stephenson Chief Financial Officer | Jul 1, 2026 | Buy | +600 | $24.22 | $14.53K | 46,688 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +4,255 | $24.98 | $106.29K | 41,688 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +1,910 | $22.95 | $43.83K | 35,795 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +1,638 | $23.88 | $39.12K | 37,433 |
| Brian C. Stephenson Chief Financial Officer | Jun 29, 2026 | Buy | +831 | $23.34 | $19.40K | 33,885 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +580 | $23.61 | $13.69K | 27,384 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +4,212 | $24.90 | $104.88K | 31,596 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +1,358 | $25.55 | $34.70K | 32,954 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +100 | $26.39 | $2.64K | 33,054 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +2,891 | $25.22 | $72.91K | 20,304 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +3,000 | $25.98 | $77.94K | 23,304 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +3,400 | $26.98 | $91.73K | 26,704 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +100 | $27.77 | $2.78K | 26,804 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +425 | $25.91 | $11.01K | 17,413 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +1,969 | $24.84 | $48.91K | 16,988 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +6,836 | $24.12 | $164.88K | 15,019 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,797 | $20.23 | $36.35K | 1,797 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +356 | $23.95 | $8.53K | 8,183 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +3,329 | $23.28 | $77.50K | 7,827 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,583 | $22.40 | $35.46K | 4,498 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,118 | $20.82 | $23.28K | 2,915 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Buy | +2,806 | $19.76 | $55.45K | 764,234 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Option exercise | +8,213 | $1.16 | $9.53K | 817,699 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Option exercise | +45,252 | $1.16 | $52.49K | 809,486 |
| Stephen M. Hahn Director | Jun 15, 2026 | Conversion | +44,763 | – | – | 44,763 |
| Anand Kiran Parikh President and CEO, Director | Jun 15, 2026 | Conversion | +761,428 | – | – | 761,428 |
| James Peyer 10% owner | Jun 1, 2026 | Sale | −476 | $21.14 | $10.06K | 130,142 |
| James Peyer 10% owner | Jun 1, 2026 | Sale | −24,524 | $20.00 | $490.48K | 130,618 |
| BioPharma Inc Cambrian 10% owner | Jun 1, 2026 | Sale | −476 | $21.14 | $10.06K | 130,142 |
| BioPharma Inc Cambrian 10% owner | Jun 1, 2026 | Sale | −24,524 | $20.00 | $490.48K | 130,618 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −1,108 | $33.38 | $36.99K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −300 | $32.25 | $9.68K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −4,423 | $31.38 | $138.79K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −205 | $29.71 | $6.09K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −2,115 | $28.94 | $61.21K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Buy | +1,108 | $33.38 | $36.99K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Buy | +1,104 | $31.02 | $34.25K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Sale | −1,214 | $31.02 | $37.66K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Sale | −45 | $31.96 | $1.44K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +701 | $35.55 | $24.92K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +26 | $33.47 | $870 | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +1,276 | $34.75 | $44.34K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −3,099 | $30.86 | $95.64K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,265 | $31.75 | $40.16K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,794 | $32.60 | $58.48K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −374 | $33.35 | $12.47K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,134 | $34.80 | $39.46K | 144,974 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +3,401 | $35.46 | $120.60K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Sale | −1,104 | $31.52 | $34.80K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Sale | −46 | $34.75 | $1.60K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +1,161 | $31.53 | $36.61K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +1,613 | $34.59 | $55.79K | 147,731 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −87 | $31.52 | $2.74K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −5 | $28.41 | $142 | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −57 | $27.11 | $1.55K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −1,251 | $25.17 | $31.49K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −191 | $24.28 | $4.64K | 146,657 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
12.76%
3M shares short
Days to cover
6.3
At 0M shares a day
Change since last report
+17.7%
From 2M shares
Short volume, 20 days
44.3%
Of volume reported to FINRA
Shares sold short, last 5 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Faeth Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 75,144 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| BioPharma Inc Cambrian 10% Stockholder | Aug 11, 2026 | 130,142 | $3.64M | Jul 22, 2026 | Private Placement |
| BioPharma Inc Cambrian 10% Stockholder | Apr 29, 2026 | 155,142 | $4.96M | Apr 29, 2026 | Private Placement |
| John Celebi Former Officer | Feb 24, 2026 | 3,374 | $116.36K | Feb 24, 2026 | Option Granted 02/15/2023 |
| James Peyer Fomer Director | Feb 18, 2026 | 950 | $25.77K | Feb 18, 2026 | Option Granted 06/11/2024 |
| William R. Ringo Former Director | Jan 27, 2026 | 1,169 | $11.49K | Jan 27, 2026 | Restricted Stock Vesting |
| James Peyer Former Director | Dec 9, 2025 | 841 | $6.71K | Dec 9, 2025 | Restricted Stock Vesting |
| BioPharma Inc Cambrian 10% Stockholder | Dec 4, 2025 | 5,844 | $50.90K | Dec 4, 2025 | Open Market Purchase |
| BioPharma Inc Cambrian 10% Stockholder | Dec 4, 2025 | 21,222 | $184.84K | Dec 4, 2025 | Open Market Purchase |
See a number that looks wrong?